Texas-based company is designed to coordinate U.S. development, pharmaceutical-grade supply and potential clinical sponsorship activities through a dedicated Psyence BioMed entity
Psyence BioMed welcomes renewed federal support for ibogaine development and outlines how its pharmaceutical manufacturing platform can contribute to responsible clinical research in the United States.
Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company focused on the development and supply of nature-derived psychedelic compounds for clinical research and therapeutic applications, today announced that members of its executive leadership team will travel to the United States in the coming weeks to meet with researchers, institutions, industry leaders, and government stakeholders involved in advancing psychedelic medicine research and policy initiatives.
Psyence BioMed has begun its NPX-5 psilocybin trial, dosing the first patient in a Phase IIb study targeting adjustment disorder in palliative care.
Through its investment in and collaboration with PsyLabs, the Company has established a GMP-compliant, pharmaceutical-grade supply chain
Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities
Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities
Psyence BioMed reinforces its vertically integrated pharmaceutical platform through its investment in PsyLabs, securing GMP manufacturing, compound supply, and long term commercial infrastructure.
Psyence BioMed Put Option exercised by PsyLabs initiates a $5 million share for share exchange, deepening strategic alignment and reinforcing long term access to pharmaceutical grade psychedelic supply as clinical programs advance.
Psyence BioMed Put Option exercised by PsyLabs initiates a $5 million share for share exchange, deepening strategic alignment and reinforcing long term access to pharmaceutical grade psychedelic supply as clinical programs advance.
